Voluntis S.A.. (11/23/20). "Press Release: Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing of Its Strategic Roadmap [Not for US, CA, AU or JP] Japan.". Cambridge, MA & Paris.

	Organisation	Voluntis S.A. (Euronext Paris: VTX)
	Group	Voluntis (Group)
	Organisation 2	Debiopharm Innovation Fund S.A.
	Group	Debiopharm (Group)
	Product	digital health
	Product 2	venture capital
	Index term	Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund
	Person	Dowe, Tanja (Debiopharm 201705 Head of Debiopharm Innovation Fund)

Original document
accessed by [iito] on 2020-11-24

Record changed: 2020-11-30

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Voluntis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)